Reconstituted HDL nanoparticles were loaded with siRNAs against two key cancer genes and administered intravenously into orthotopic mouse models of cancer, and were able to effectively silence the expression of their targets.
The presentation will focus on data from an ongoing phase I study with Atu027 in subjects with advanced solid cancer. “Key findings presented will include safety, tolerability and pharmacokinetic data, as well as indications of anti-tumor activity,” Silence said.
The phase I drug, ALN-VSP02, comprises two siRNAs, one targeting vascular endothelial growth factor and one targeting kinesin spindle protein, both of which the firm said are critical for the growth and survival of cancer cells.
Notably, the patent in dispute is part of the so-called Zamore IP family. Alnylam's top official earlier this year publicly dismissed a related US patent from the Zamore family as "not worth anything."